Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCRT + nimotuzumab followed by camrelizumab for unresectable locally advanced esophageal cancer
ChiCTR2600124522Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab and camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Progression-free survival (PFS). Started May 2026; status: recruiting.
02
Drugs
nimotuzumabcamrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600124522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124522.